Nautilus Biotechnolgy/NAUT

$2.95

1.02%
-
1D1W1MYTD1YMAX

About Nautilus Biotechnolgy

Nautilus Biotechnology, Inc. is a development stage life sciences company. The Company is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company is focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. The Company's platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The Company’s products include Proteome Analysis System, and Reagent Kits. Its proteome analysis system is a high-resolution optical imaging system coupled with integrated fluidics and liquid handling sub-systems. The Company’s Reagent Kits are comprised of four main components: sample preparation, flow cell(s), multi-affinity probe reagents, and instrument buffers used to perform multi-cycle analysis runs.

Ticker

NAUT

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Sujal Patel

Employees

163

Headquarters

Seattle, United States

NAUT Metrics

BasicAdvanced
$360M
Market cap
-
P/E ratio
-$0.54
EPS
1.07
Beta
-
Dividend rate
$360M
1.07497
$4.65
$2.27
76K
20.093
-21.26%
-24.38%
-21.85%
1.441
1.441
-17.85%

What the Analysts think about NAUT

Analyst Ratings

Majority rating from 4 analysts.
Buy

Price Targets

Average projection from 3 analysts.
44.07% upside
High $5.00
Low $2.75
$2.95
Current price
$4.25
Average price target

NAUT Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$19M
10%
Profit margin
0%
NaN%

NAUT Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.69%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.13
-$0.13
-$0.14
-$0.15
-
Expected
-$0.15
-$0.17
-$0.15
-$0.16
-$0.17
Surprise
-13.33%
-22.39%
-3.45%
-7.69%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Nautilus Biotechnolgy stock?

Nautilus Biotechnolgy (NAUT) has a market cap of $360M as of May 18, 2024.

What is the P/E ratio for Nautilus Biotechnolgy stock?

The price to earnings (P/E) ratio for Nautilus Biotechnolgy (NAUT) stock is 0 as of May 18, 2024.

Does Nautilus Biotechnolgy stock pay dividends?

No, Nautilus Biotechnolgy (NAUT) stock does not pay dividends to its shareholders as of May 18, 2024.

When is the next Nautilus Biotechnolgy dividend payment date?

Nautilus Biotechnolgy (NAUT) stock does not pay dividends to its shareholders.

What is the beta indicator for Nautilus Biotechnolgy?

Nautilus Biotechnolgy (NAUT) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Nautilus Biotechnolgy stock price target?

The target price for Nautilus Biotechnolgy (NAUT) stock is $4.25, which is 44.07% above the current price of $2.95. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Nautilus Biotechnolgy stock

Buy or sell Nautilus Biotechnolgy stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing